Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma-Reference-Cited by-同舟云学术

Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma

Published:2015-03-04 Issue:1 Volume:8 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

Zhu Jiang,He Shiping,Du Jie,Wang Zhulin,Li Wang,Chen Xianxiong,Jiang Wenqi,Zheng Duo,Jin Guangyi

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

http://link.springer.com/content/pdf/10.1186/s13045-015-0121-9.pdf

Reference27 articles.

1. Rezvani AR, Maloney DG. Rituximab resistance. Best Pract Res Clin Haematol. 2011;24(2):203–16. doi:10.1016/j.beha.2011.02.009.

2. Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy. 2009;1(6):949–64. doi:10.2217/imt.09.70.

3. Boonstra A, Asselin-Paturel C, Gilliet M, Crain C, Trinchieri G, Liu YJ, et al. Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation. J Exp Med. 2003;197(1):101–9.

4. Qi H, Denning TL, Soong L. Differential induction of interleukin-10 and interleukin-12 in dendritic cells by microbial toll-like receptor activators and skewing of T-cell cytokine profiles. Infect Immun. 2003;71(6):3337–42.

5. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4 + CD25+ T cell-mediated suppression by dendritic cells. Science. 2003;299(5609):1033–6. doi:10.1126/science.1078231.

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single-domain antibodies as therapeutics for solid tumor treatment;Acta Pharmaceutica Sinica B;2024-07

2. The novel selective TLR7 agonist GY101 suppresses colon cancer growth by stimulating immune cells;European Journal of Pharmacology;2024-03

3. Role of cytokine in malignant T-cell metabolism and subsequent alternation in T-cell tumor microenvironment;Frontiers in Oncology;2023-09-07

4. Therapeutic treatment with phosphodiesterase-4 inhibitors alleviates kidney injury and renal fibrosis by increasing MMP-9 in a doxorubicin-induced nephrotoxicity mouse model;International Immunopharmacology;2023-02

5. The Role of TRL7/8 Agonists in Cancer Therapy, with Special Emphasis on Hematologic Malignancies;Vaccines;2023-01-28